Market Intelligence, Clinical Progress, and High-Purity Reagents for Arrhythmia and Ataxia Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KCND3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KCND3 Membrane Preparation / Mutant. High purity, Sequence Verified, HEK293 Expressed (Native Conformation). | View KCND3 Products |
| Gene Delivery | KCND3 Lentivirus Particles. Full-length ORF (NM_004980) for stable cell line generation. Sequence Verified, HEK293T packaged. High titer (>10^8 TU/mL). | View KCND3 Products |
| Mutant Library | KCND3 Brugada/Ataxia Variants. Traffic-deficient mutants (e.g., R291H, P429fs) for rescue assay development. Sequence Verified. | View KCND3 Products |
| Auxiliary Subunit | KCNIP2 (KChIP2) Co-expression Vector. Essential accessory subunit for KCND3 trafficking and gating. Full-length ORF. | View KCNIP2 Products |
| Benchmark Ab | Anti-KCND3 Recombinant Antibody (Research Grade). Sequence-defined mAb for Western blot and ICC validation. | View KCND3 Products |
| Validator | KCND3 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. HPLC purified. | View KCND3 Products |
| Related Target A (Kv4.2) | KCND2 (Kv4.2). Cardiac/neuronal isoform with overlapping function. Critical for selectivity profiling. | View KCND2 Products |
| Related Target B (Kv4.1) | KCND1 (Kv4.1). Neuronal-specific isoform. Off-target liability counter-screening. | View KCND1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Trafficking Deficiency (Brugada Syndrome mutants) | Lentiviral delivery of trafficking-competent WT and mutant constructs; Compatible with high-content imaging assays for surface expression quantification. |
| Kv4 Family Selectivity (Kv4.1/4.2 vs Kv4.3) | Human KCND1/KCND2/KCND3 ortholog panel available; Sequence verified for precise epitope mapping. |
| Auxiliary Subunit Dependence | Matched KCNIP2 (KChIP2) co-expression vectors; HEK293 expressed for native post-translational modification compatibility. |
| False Positives in Electrophysiology | Validated KCND3 siRNA included for target-specificity verification; Sequence-verified controls. |
Live KCND3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Brugada Syndrome Research
- Spinocerebellar Ataxia Mechanisms
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The KCND3 target landscape is defined by its critical role in cardiac transient outward potassium current (Ito) and neuronal A-type current. Loss-of-function mutations cause Brugada Syndrome Type 9 (BrS9) and Spinocerebellar Ataxia type 19/22 (SCA19/22), creating unmet needs for trafficking correctors and isoform-selective modulators. Unlike druggable enzyme targets, KCND3 requires sophisticated cell-based electrophysiology platforms, as recombinant protein alone cannot recapitulate voltage-dependent gating and auxiliary subunit interactions. Current R&D trends indicate a shift toward precision medicine: mutation-specific rescue therapies for Brugada variants and neuron-selective modulators for ataxia that spare cardiac tissue. The emergence of high-throughput automated patch-clamp (HTS-APC) and cryo-EM structural insights have revitalized ion channel drug discovery, enabling the development of allosteric modulators targeting gating kinetics. Future directions include mutant stratification, auxiliary subunit targeting (e.g., KChIP2), combination therapies with SCN5A modulators, and integration of iPSC disease models for personalized screening.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Trafficking Corrector | Academic consortia, Rare disease foundations | Brugada Syndrome (Loss-of-function) | Cell-based trafficking rescue assay using mutant KCND3 lentivirus in HEK293 or iPSC-cardiomyocytes. |
| Isoform-Selective Channel Blocker | Biotech specializing in pain/neurology | Spinocerebellar Ataxia (Hyperexcitability) | Selectivity panel: KCND1/KCND2/KCND3 family counter-screen with lentivirus-stable cell lines. |
| Auxiliary Subunit Modulator | Targeted protein interaction platforms | Heart Failure (Ito modulation) | KCNIP2 co-expression system; KChIP2-KCND3 interaction assays. |
| Gene Therapy (AAV) | AAV-based CNS delivery programs | SCA19/22 (Genetic correction) | Wild-type KCND3 lentivirus for proof-of-concept rescue studies in vitro. |
| Peptide Toxin | Academic/Niche Pharma | Targeted Arrhythmia | Subtype selectivity: KCND2/KCNIP2 co-expression panels. |